Leuven, BELGIUM, Boston, MA, US -September 7, 2022 -8.00 am CETOxurion NV(Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today published its financial and business update for the six-month period ending June 30, 2022.
The half-year report is available in the "Investors" section of the Company's website and can also be downloaded as a PDF.
About Oxurion
Oxurion.
For further information please contact:
| Oxurion NV Tom Graney Chief Executive Officer Tel: +32 16 75 13 10 tom.graney@oxurion.com Michael Dillen Chief Business Officer Tel: +32 16 75 14 69 michael.dillen@oxurion.com | US Conway Communications Beth Kurth bkurth@conwaycommsir.com ICR Westwicke Christopher Brinzey Tel: +1 617 835 9304 Chris.Brinzey@westwicke.com |
Attachment
- OXUR 1H 2022 2022.0907 FINAL (https://ml-eu.globenewswire.com/Resource/Download/c78781ac-4fde-499d-a32b-69a473eb9572)
© 2022 GlobeNewswire (Europe)
